{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T05:05:59Z","timestamp":1782536759076,"version":"3.54.5"},"reference-count":32,"publisher":"Institute of Physiology of the Czech Academy of Sciences","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Physiol Res"],"published-print":{"date-parts":[[2011,8,31]]},"abstract":"<jats:p>The aim of our study was to measure serum concentrations of fibroblast growth factor 19 (FGF-19) in patients with obesity (OB), obesity and type 2 diabetes mellitus (T2DM) and healthy subjects (C) at baseline and after selected interventions. We measured serum FGF-19 levels and other biochemical and hormonal parameters in 29 OB and 19 T2DM females and 30 sex- and age-matched control subjects. The interventions were acute hyperinsulinemia during isoglycemic-hyperinsulinemic clamp (n=11 for T2DM and 10 for C), very-low calorie diet (VLCD, n=12 for OB) and 3 months treatment with PPAR-\u03b1 agonist fenofibrate (n=11 for T2DM). Baseline serum FGF-19 levels were significantly lower in OB relative to C group (132.1\u00b112.7 vs. 202.2\u00b116.7 pg\/ml, p&lt;0.05), while no significant difference was observed between T2DM and OB or control group. Acute hyperinsulinemia tended to decrease FGF-19 levels in both healthy and T2DM subjects. Three weeks of VLCD in OB group had no significant effect on FGF-19, whereas three months of fenofibrate treatment markedly reduced FGF-19 levels in T2DM patients (194.58\u00b126.2 vs. 107.47\u00b125.0 pg\/ml, p&lt;0.05). We conclude that FGF-19 levels in our study were at least partially dependent upon nutritional status, but were not related to parameters of glucose metabolism or insulin sensitivity.<\/jats:p>","DOI":"10.33549\/physiolres.932099","type":"journal-article","created":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T10:34:29Z","timestamp":1580553269000},"page":"627-636","source":"Crossref","is-referenced-by-count":66,"title":["Serum Concentrations of Fibroblast Growth Factor 19 in Patients With Obesity and Type 2 Diabetes Mellitus: the Influence of Acute Hyperinsulinemia, Very-Low Calorie Diet and PPAR-\u03b1 Agonist Treatment"],"prefix":"10.33549","author":[{"given":"M.","family":"MR\u00c1Z","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Z.","family":"LACINOV\u00c1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"KAV\u00c1LKOV\u00c1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"HALUZ\u00cdKOV\u00c1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"TRACHTA","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"DR\u00c1PALOV\u00c1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"HANU\u0160OV\u00c1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"HALUZ\u00cdK","sequence":"additional","affiliation":[{"name":"Third Department of Medicine, General University Hospital and First Medical Faculty, Charles University, Prague, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"19169","published-online":{"date-parts":[[2011,8,17]]},"reference":[{"key":"ref0","doi-asserted-by":"crossref","unstructured":"ANDERLOVA K, DOLEZALOVA R, HOUSOVA J, BOSANSKA L, HALUZIKOVA D, KREMEN J, SKRHA J, HALUZIK M: Influence of PPAR-alpha agonist fenofibrate on insulin sensitivity and selected adipose tissue-derived hormones in obese women with type 2 diabetes. Physiol Res 56: 579-586, 2007.","DOI":"10.33549\/physiolres.931058"},{"key":"ref1","doi-asserted-by":"publisher","unstructured":"ANDERLOVA K, KREMEN J, DOLEZALOVA R, HOUSOVA J, HALUZIKOVA D, KUNESOVA M, HALUZIK M: The influence of very-low-calorie-diet on serum leptin, soluble leptin receptor, adiponectin and resistin levels in obese women. Physiol Res 55: 277-283, 2006.","DOI":"10.1081\/erc-200034301"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"BEIL U, CROUSE JR, EINARSSON K, GRUNDY SM: Effects of interruption of the enterohepatic circulation of bile acids on the transport of very low density-lipoprotein triglycerides. Metabolism 31: 438-444, 1982.","DOI":"10.1016\/0026-0495(82)90231-1"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"BRUFAU G, STELLAARD F, PRADO K, BLOKS VW, JONKERS E, BOVERHOF R, KUIPERS F, MURPHY EJ: Improved glycemic control with colesevelam treatment in patients with type 2 diabetes is not directly associated with changes in bile acid metabolism. Hepatology 52: 1455-1464, 2010.","DOI":"10.1002\/hep.23831"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"CARIOU B, VAN HARMELEN K, DURAN-SANDOVAL D, VAN DIJK TH, GREFHORST A, ABDELKARIM M, CARON S, TORPIER GR, FRUCHART J-C, GONZALEZ FJ, KUIPERS F, STAELS B: The farnesoid X receptor modulates adiposity and peripheral insulin sensitivity in mice. J Biol Chem 281: 11039-11049, 2006.","DOI":"10.1074\/jbc.m510258200"},{"key":"ref5","unstructured":"DOSTALOVA I, KAVALKOVA P, HALUZIKOVA D, LACINOVA Z, MRAZ M, PAPEZOVA H, HALUZIK M: Plasma concentrations of fibroblast growth factors 19 and 21 in patients with anorexia nervosa. J Clin Endocrinol Metab 93: 3627-3632, 2008a."},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"FU L, JOHN LM, ADAMS SH, YU XX, TOMLINSON E, RENZ M, WILLIAMS PM, SORIANO R, CORPUZ R, MOFFAT B, VANDLEN R, SIMMONS L, FOSTER J, STEPHAN J-P, TSAI SP, STEWART TA: Fibroblast growth factor 19 increases metabolic rate and reverses dietary and leptin-deficient diabetes. Endocrinology 145: 2594-2603, 2004.","DOI":"10.1210\/en.2003-1671"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"HALUZIK MM, ANDERLOVA K, DOLEZALOVA R, ADAMIKOVA A, HALUZIKOVA D, HOUSOVA J, SVACINA S, HALUZIK M: Serum adipocyte fatty acid binding protein levels in patients with type 2 diabetes mellitus and obesity: the influence of fenofibrate treatment. Physiol Res 58: 93-99, 2009.","DOI":"10.33549\/physiolres.931371"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"HOLT JA, LUO G, BILLIN AN, BISI J, MCNEILL YY, KOZARSKY KF, DONAHEE M, WANG DY, MANSFIELD TA, KLIEWER SA, GOODWIN B, JONES SA: Definition of a novel growth factor-dependent signal cascade for the suppression of bile acid biosynthesis. Genes Dev 17: 1581-1591, 2003.","DOI":"10.1101\/gad.1083503"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"CHOI M, MOSCHETTA A, BOOKOUT AL, PENG L, UMETANI M, HOLMSTROM SR, SUINO-POWELL K, XU HE, RICHARDSON JA, GERARD RD, MANGELSDORF DJ, KLIEWER SA: Identification of a hormonal basis for gallbladder filling. Nat Med 12: 1253-1255, 2006.","DOI":"10.1038\/nm1501"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"INAGAKI T, CHOI M, MOSCHETTA A, PENG L, CUMMINS CL, MCDONALD JG, LUO G, JONES SA, GOODWIN B, RICHARDSON JA, GERARD RD, REPA JJ, MANGELSDORF DJ, KLIEWER SA: Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis. Cell Metab 2: 217-225, 2005.","DOI":"10.1016\/j.cmet.2005.09.001"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"INSULL W JR: Clinical utility of bile acid sequestrants in the treatment of dyslipidemia: a scientific review. South Med J 99: 257-273, 2006.","DOI":"10.1097\/01.smj.0000208120.73327.db"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"ITOH N, ORNITZ DM: Evolution of the Fgf and Fgfr gene families. Trends Genet 20: 563-569, 2004.","DOI":"10.1016\/j.tig.2004.08.007"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"LEFEBVRE P, CARIOU B, LIEN F, KUIPERS F, STAELS B: Role of bile acids and bile acid receptors in metabolic regulation. Physiol Rev 89: 147-191, 2009.","DOI":"10.1152\/physrev.00010.2008"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"LUNDASEN T, GALMAN C, ANGELIN B, RUDLING M: Circulating intestinal fibroblast growth factor 19 has a pronounced diurnal variation and modulates hepatic bile acid synthesis in man. J Intern Med 260: 530-536, 2006.","DOI":"10.1111\/j.1365-2796.2006.01731.x"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"MA K, SAHA PK, CHAN L, MOORE DD: Farnesoid X receptor is essential for normal glucose homeostasis. J Clin Invest 116: 1102-1109, 2006.","DOI":"10.1172\/jci25604"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"MATTHEWS DR, HOSKER JP, RUDENSKI AS, NAYLOR BA, TREACHER DF, TURNER RC: Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28: 412-419, 1985.","DOI":"10.1007\/bf00280883"},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"NISHIMURA T, UTSUNOMIYA Y, HOSHIKAWA M, OHUCHI H, ITOH N: Structure and expression of a novel human FGF, FGF-19, expressed in the fetal brain. Biochim Biophys Acta 1444: 148-151, 1999.","DOI":"10.1016\/s0167-4781(98)00255-3"},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"PINEDA TORRA I, CLAUDEL T, DUVAL C, KOSYKH V, FRUCHART J-C, STAELS B: Bile acids induce the expression of the human peroxisome proliferator-activated receptor {alpha} gene via activation of the farnesoid X receptor. Mol Endocrinol 17: 259-272, 2003.","DOI":"10.1210\/me.2002-0120"},{"key":"ref19","doi-asserted-by":"publisher","unstructured":"REICHE M, BACHMANN A, L\u00d6SSNER U, BL\u00dcHER M, STUMVOLL M, FASSHAUER M: Fibroblast growth factor 19 serum levels: relation to renal function and metabolic parameters. Horm Metab Res 42: 178-181, 2010.","DOI":"10.1055\/s-0029-1243249"},{"key":"ref20","doi-asserted-by":"publisher","unstructured":"RONTI T, LUPATTELLI G, MANNARINO E: The endocrine function of adipose tissue: an update. Clin Endocrinol (Oxf) 64: 355-365, 2006.","DOI":"10.1111\/j.1365-2265.2006.02474.x"},{"key":"ref21","doi-asserted-by":"publisher","unstructured":"SHEPHERD J, PACKARD CJ, BICKER S, LAWRIE TDV, MORGAN HG: Cholestyramine promotes receptor-mediated low-density-lipoprotein catabolism. N Engl J Med 302: 1219-1222, 1980.","DOI":"10.1056\/nejm198005293022202"},{"key":"ref22","doi-asserted-by":"publisher","unstructured":"SHIN DJ, OSBORNE TF: FGF15\/FGFR4 integrates growth factor signaling with hepatic bile acid metabolism and insulin action. J Biol Chem 284: 11110-11120, 2009.","DOI":"10.1074\/jbc.m808747200"},{"key":"ref23","doi-asserted-by":"publisher","unstructured":"SCHAAP FG, VAN DER GAAG NA, GOUMA DJ, JANSEN PL: High expression of the bile salt-homeostatic hormone fibroblast growth factor 19 in the liver of patients with extrahepatic cholestasis. Hepatology 49: 1228-1235, 2009.","DOI":"10.1002\/hep.22771"},{"key":"ref24","doi-asserted-by":"publisher","unstructured":"SCHREUDER TC, MARSMAN HA, LENICEK M, VAN WERVEN JR, NEDERVEEN AJ, JANSEN PL, SCHAAP FG: The hepatic response to FGF19 is impaired in patients with nonalcoholic fatty liver disease and insulin resistance. Am J Physiol Gastrointest Liver Physiol 298: G440-G445, 2010.","DOI":"10.1152\/ajpgi.00322.2009"},{"key":"ref25","doi-asserted-by":"crossref","unstructured":"SMELT AHM: Triglycerides and gallstone formation. Clin Chim Acta 411: 1625-1631, 2010.","DOI":"10.1016\/j.cca.2010.08.003"},{"key":"ref26","doi-asserted-by":"publisher","unstructured":"STUMVOLL M, JACOB S, WAHL HG, HAUER B, LOBLEIN K, GRAUER P, BECKER R, NIELSEN M, RENN W, HARING H: Suppression of systemic, intramuscular, and subcutaneous adipose tissue lipolysis by insulin in humans. J Clin Endocrinol Metab 85: 3740-3745, 2000.","DOI":"10.1210\/jcem.85.10.6898"},{"key":"ref27","doi-asserted-by":"publisher","unstructured":"TOMLINSON E, FU L, JOHN L, HULTGREN B, HUANG X, RENZ M, STEPHAN JP, TSAI SP, POWELL-BRAXTON L, FRENCH D, STEWART TA: Transgenic mice expressing human fibroblast growth factor-19 display increased metabolic rate and decreased adiposity. Endocrinology 143: 1741-1747, 2002.","DOI":"10.1210\/endo.143.5.8850"},{"key":"ref28","doi-asserted-by":"publisher","unstructured":"XIE MH, HOLCOMB I, DEUEL B, DOWD P, HUANG A, VAGTS A, FOSTER J, LIANG J, BRUSH J, GU Q, HILLAN K, GODDARD A, GURNEY AL: FGF-19, a novel fibroblast growth factor with unique specificity for FGFR4. Cytokine 11: 729-735, 1999.","DOI":"10.1006\/cyto.1999.0485"},{"key":"ref29","doi-asserted-by":"publisher","unstructured":"YU C, WANG F, JIN C, HUANG X, MCKEEHAN WL: Independent repression of bile acid synthesis and activation of c-Jun N-terminal kinase (JNK) by activated hepatocyte fibroblast growth factor receptor 4 (FGFR4) and bile acids. J Biol Chem 280: 17707-17714, 2005.","DOI":"10.1074\/jbc.m411771200"},{"key":"ref30","doi-asserted-by":"publisher","unstructured":"YU C, WANG F, KAN M, JIN C, JONES RB, WEINSTEIN M, DENG C-X, MCKEEHAN WL: Elevated cholesterol metabolism and bile acid synthesis in mice lacking membrane tyrosine kinase receptor FGFR4. J Biol Chem 275: 15482-15489, 2000.","DOI":"10.1074\/jbc.275.20.15482"},{"key":"ref31","doi-asserted-by":"publisher","unstructured":"ZHANG Y, LEE FY, BARRERA G, LEE H, VALES C, GONZALEZ FJ, WILLSON TM, EDWARDS PA: Activation of the nuclear receptor FXR improves hyperglycemia and hyperlipidemia in diabetic mice. Proc Natl Acad Sci U S A 103: 1006-1011, 2006.","DOI":"10.1073\/pnas.0506982103"}],"container-title":["Physiological Research"],"original-title":[],"language":"en","deposited":{"date-parts":[[2022,10,13]],"date-time":"2022-10-13T21:01:20Z","timestamp":1665694880000},"score":1,"resource":{"primary":{"URL":"http:\/\/biomed.cas.cz\/physiolres\/pdf\/60\/60_627.pdf"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,8,17]]},"references-count":32,"URL":"https:\/\/doi.org\/10.33549\/physiolres.932099","relation":{},"ISSN":["1802-9973","0862-8408"],"issn-type":[{"value":"1802-9973","type":"electronic"},{"value":"0862-8408","type":"print"}],"subject":[],"published":{"date-parts":[[2011,8,17]]}}}